Concepedia

Publication | Open Access

Alemtuzumab CARE-MS I 5-year follow-up

DOIFull Paper Access

222

Citations

19

References

2017

Year

Eva Havrdová, Douglas L. Arnold, Jeffrey Cohen, Hans‐Peter Hartung, Edward Fox, Gavin Giovannoni, Sven Schippling, Krzysztof Selmaj, Anthony Traboulsee, D. A. S. Compston,
Neurology

Abstract

This study provides Class III evidence that alemtuzumab durably improves efficacy outcomes and slows BVL in patients with RRMS.

References

YearCitations

Page 1